Gastroenterology

Top Medical News
Audrey Abella, 14 hours ago
Amiselimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, demonstrated a favourable safety profile among healthy individuals, according to a phase I study presented at Crohn’s and Colitis 2021.
Pearl Toh, Yesterday
While children with inflammatory bowel disease (IBD) see their conditions improve with biologic therapy, those with ulcerative colitis (UC) tend to have residual disease activity even after clinical remission, according to two separate studies presented at the 2021 Crohn’s and Colitis Congress.
Yesterday
Progression-free (PFS) and overall survival (OS) are significantly lower in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib and concomitant gastric acid suppression therapy, a recent study has found.
Yesterday
Transjugular intrahepatic portosystemic shunt (TIPS) is superior to endoscopic band ligation (EBL) and other nonsurgical secondary prophylaxis interventions in reducing the incidence of cirrhosis oesophageal varices (EV) rebleeding, rebleeding-related mortality, and overall mortality in cirrhosis, results of a study have shown.
Audrey Abella, Yesterday
A meta-analysis presented at Crohn’s and Colitis 2021 demonstrated reductions in disease activity among adults with Crohn’s disease (CD) who were taking antibiotics.
Elaine Soliven, 2 days ago
Patients with ulcerative colitis (UC) who received a subcutaneous (SC) formulation of vedolizumab as maintenance therapy achieved clinical remission at 52 weeks, according to the VISIBLE 1* trial presented at AIBD 2020.
Stephen Padilla, 2 days ago
Children infected with SARS-CoV-2, the causative agent of the coronavirus disease 2019 (COVID-19), may also develop acute appendicitis, according to a study.
Special Reports
10 Mar 2020
RB Health is committed to support healthcare quality improvement through CME activities that help physicians stay updated with the latest developments in medicine. At the RB symposium held in Kuala Lumpur, two distinguished speakers gave their insights into the management of acid reflux and sore throat – two of the most common reasons for patients to visit their doctors.
26 Nov 2019
At the recent Takeda Malaysia Vocinti® (vonoprazan) launch, held in conjunction with the Annual Scientific Meeting of the Malaysian Society of Gastroenterology and Hepatology - GUT 2019 at Shangri-La Kuala Lumpur, Professor Akihito spoke about vonoprazan’s merits as an alternative to conventional proton pump inhibitors.
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

17 Jul 2019
All Helicobacters are urease-positive, able to convert aminoacids and urea into ammonia to neutralize stomach acid, andhighly mobile – characteristics that help them invade the mucosallayer to evade the body’s immune response. Helicobacter pylori(H. pylori) is linked to peptic ulcer disease, chronic gastritis,gastric mucosa-associated lymphoid tissue lymphoma, andearly gastric cancer. The infection rate of H. pylori is over 80% indeveloping countries and 20–50% in industrialized nations, withover 4.4 billion people testing positive for the bacteria in 2015.1,2
Conference Reports
Pearl Toh, 26 Jan 2021
While children with inflammatory bowel disease (IBD) see their conditions improve with biologic therapy, those with ulcerative colitis (UC) tend to have residual disease activity even after clinical remission, according to two separate studies presented at the 2021 Crohn’s and Colitis Congress.
Audrey Abella, 26 Jan 2021
A meta-analysis presented at Crohn’s and Colitis 2021 demonstrated reductions in disease activity among adults with Crohn’s disease (CD) who were taking antibiotics.
Elaine Soliven, 26 Jan 2021
Patients with ulcerative colitis (UC) who received a subcutaneous (SC) formulation of vedolizumab as maintenance therapy achieved clinical remission at 52 weeks, according to the VISIBLE 1* trial presented at AIBD 2020.
Pearl Toh, 21 Jan 2021
The oral selective sphingosine-1-phosphate (S1P) receptor modulator ozanimod induced significant improvements in clinical remission and response, which were sustained up to 52 weeks, in patients with moderate-to-severe ulcerative colitis (UC), according to the phase III True North study presented at AIBD 2020 Congress.
Pearl Toh, 19 Jan 2021
Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.
Audrey Abella, 18 Jan 2021
An inverse association was found between the use of proton pump inhibitors (PPIs) and the severity of periodontal disease (PD), according to data presented at AIBD 2020.
Audrey Abella, 14 Jan 2021
Removal of the gallbladder (ie, cholecystectomy) is not recommended at the time of intestinal resection among individuals with inflammatory bowel disease (IBD), according to data presented at AIBD 2020.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download